By Fineline Cube 
China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its ASC50. This oral small molecule interleukin 17 (IL17) inhibitor will be evaluated in patients with mild to moderate plaque psoriasis, with the study expected to commence during the third quarter of this year.
ASC50 Mechanism and Advantages
ASC50 is designed as an oral small molecule inhibitor targeting interleukin 17 (IL17), a key cytokine involved in inflammatory pathways. Preclinical data indicates that ASC50 offers higher oral exposure, a longer half-life, and strong efficacy compared to similar investigational products. These attributes suggest that ASC50 has the potential to provide effective and convenient treatment for patients with psoriasis.
Clinical Trial Objectives
The Phase I study will primarily assess the safety, tolerability, and pharmacokinetics of ASC50 in patients with mild to moderate plaque psoriasis. The findings from this trial will help determine the optimal dosing regimen and provide preliminary evidence of the drug’s efficacy.-Fineline Info & Tech